Merck photo: PR Merck sets up €20m fund for Israeli biotech cos

The German pharmaceutical company is cooperating with Arkin Bio Ventures, Pontifax Fund, and WuXi Apptec.

Vaica Photo: PR Vaica reminds patients to take medicine

The Israeli company adapts its reminders to the patient's age and the type of medicine.

Ziv Aviram and Prof. Amnon Shashua Mobileye founders co OrCam valued at over $1b

OrCam, which has developed a wearable aid for people with impaired vision, raised $30.4 million in a round led by Clal Insurance and Meitav Dash Provident Funds and Pension Ltd.

Nasdaq Photo: Reuters Colonoscopy device co Motus GI raises $17.5m on Nasdaq

Tirat Hacarmel based Motus GI has developed Pure-Vu for cleaning the colon in advance of a colonoscopy.

medical equipment  photo: Shutterstock Neurovascular device co Perflow Medical raises $12m

Stream Net is a thrombectomy device designed to address unmet clinical needs in the treatment of acute ischemic stroke.

Teva Photo: Reuters Cramer shocked by Buffett's investment in "second-rate" Teva

Financial pundit Jim Cramer told CNBC that "It is amazing that Warren Buffett goes for what I largely regard as the worst of the worst."

Health Photo: Shutterstock ASAP Creative DreaMed Diabetes decision platform receives CE mark

Advisor Pro supports personalized insulin therapy planning for people with Type 1 diabetes that use insulin pumps.

Warren Buffett Photo: ASAP Creative Buffett boosts Teva with $358m investment

Teva's share price is soaring after Berkshire Hathaway reported buying a 1.8% stake in the Israeli pharmaceutical company.

drug development Galmed plunges after failed AIDS drug trial

The company is still testing its drug for treatment of fatty liver.

China China's Ogawa sets up Israel investment fund

The $10 million fund will invest in digital health and quality of life.

Cannabis Israeli cannabis analysis co GemmaCert raises $2.25m

GemmaCert allows any person to analyze and obtain accurate results on potency and quality in about 30 seconds.

Copaxone Momenta receives approval for 40mg generic Copaxone

IBI Investment: The new competition will cost Teva $0.15 per share in profit in 2018.

Philips HQ, photo: Reuters Philips Healthcare expanding its Israel workforce

The company is hiring employees for its cancer informatics division in Israel.

Teva Photo: Tamar Matsafi Teva CFO promises better days ahead

With generic drug prices falling sharply in the US and a potential delay in FDA approval for Teva's migraine treatment, Michael McClellan insists the company will soon be on solid ground.

Nasdaq Photo: Reuters Israeli co PolyPid files for $86m Nasdaq IPO

PolyPid is a clinical-stage pharmaceutical company with an initial focus on antibiotics for the prevention and treatment of post-surgical site infections.

Teva Photo: Reuters Capital Research reaches 12% stake in Teva

Foreign parties at interest now own 28.5% of the company.

Freddy Zinger Photo: Eyal Yitzhar Former Teva exec sets up Galilee incubator

Freddy Zinger does not rule out buying Teva Migada in Kiryat Shmona, the company he founded.

Kare Schultz Photo: PR Teva share price up 75% since Schultz became CEO

Kare Schultz has stabilized the ship but faces enormous opposition to his streamlining plan.

Teva Photo: Reuters Teva: Healthy business, sick share

Every change in Teva's business is amplified in its share price.

Prof Eyal Winter  photo: private Israeli drug exploration partnership can save Teva

Teva, Israel's universities and the state should join forces to find and develop new drugs, says Prof. Eyal Winter.

Teva workers demonstrate  photo: courtesy Histadrut Economic damage from Teva's cutbacks will mainly be local

Teva's contribution to Israel's tax revenues has been virtually zero.

Teva Photo: Tamar Matsafi Most Teva Israel layoffs expected at Petah Tikva HQ

As Teva workers await the axe, one tells "Globes" that he fears he will be shortchanged while outgoing CSO Michael Hayden gets $2.5 million by the end of 2018.

Teva Photo: Tamar Matsafi "Teva's senior execs should pay back excessive salaries"

Former Teva chairman Meir Heth believes the company's top executives are responsible for the current situation.

Teva Photo: Tamar Matsafi US hedge funds reduce Teva exposure

Some financial institutions see an opportunity in Teva's low share price and have increased their holdings in the company.

Dalton Conley Photo: PR "Genetic inequality is increasing"

Princeton University's Prof. Dalton Conley tells "Globes" that understanding the interaction between genetics and environment will start a social revolution.

Teva  photo: Reuters Poalim IBI: Teva must raise capital

Analyst Steven Tepper tells "Globes" that if Teva wants to stay independent, it needs capital, or it will be exposed to a takeover.

Prof. Zelig Eshar Photo: Shlomi Yosef Israeli professors fight for Kite Pharma sale spoils

Prof. Gideon Gross is suing Prof. Zelig Eshhar, alleging that Eshhar cheated him out of his share of the $11.9 billion sale of Kite, which has developed a revolutionary cancer drug.

Arie Belldegrun Photo: PR "Chemotherapy will become just a bad memory"

More energetic than ever, Arie Belldegrun talks to "Globes" about Kite Pharma's remarkable journey and the future of cancer treatment.

Mori Arkin, Uri Geiger photos: Tamar Matsafi, Eyal Izhar Accelmed fattening Cogentix for sale

Accelmed seeks to replicate its success formula in urology, as portfolio company Cogentix makes a third acquisition.

Essence Group  photo: PR Smart home means safe home for seniors

Israeli company Essence develops products that enable people to keep living at home in old age.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018